



- (51) **International Patent Classification:**
A61K 39/015 (2006.01) *C07K 14/445* (2006.01)
- (21) **International Application Number:**
PCT/EP2013/052557
- (22) **International Filing Date:**
8 February 2013 (08.02.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/596,931 9 February 2012 (09.02.2012) US
- (71) **Applicant:** VAR2 PHARMACEUTICALS APS
[DK/DK]; c/o Cobis, Ole Maaløes Vej 3, DK-2200 Copenhagen N (DK).
- (72) **Inventors:** SALANTI, Ali; Smørumvej 50, DK-2700 Brønshøj (DK). THEANDER, Thor, Grundtvig; Søfrydsvej 10, DK-2670 Greve (DK). DAUGAARD, Mads; 1374 Island Park Walk, Vancouver, British Columbia V6H 3T5 (CA). NIELSEN, Morten; Traneholmen 15, DK-3460 Birkerød (DK). DAHLBÄCK, Madeleine; Bremadsvägen 88, S-23391 Swedala (SE). CLAUSEN, Thomas, Mandel; Nikolajgade 20, 3. tv., DK-1068 Copenhagen K (DK).
- (74) **Agents:** HANSEN, Carsten et al.; Inspicos A/S, P.O. Box 45, Kogle Allé 2, DK-2970 Hørsholm (DK).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** TARGETING OF CHONDROITIN SULFATE GLYCANS

(57) **Abstract:** The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

